Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Revance Therapeutics (RVNC)
:RVNC
Holding RVNC?
Track your performance easily
RVNC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.30 - $7.56
Previous CloseN/A
Volume1.24M
Average Volume (3M)3.36M
Market Cap
$343.44M
Enterprise Value$839.77M
Total Cash (Recent Filing)$185.53M
Total Debt (Recent Filing)$1.87M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Mar 04, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding104,389,885
10 Day Avg. Volume3,239,759
30 Day Avg. Volume3,364,585
Standard Deviation0.27
R-Squared0.03
Alpha-0.00469
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.40
Price to Cash Flow (P/CF)-2.10
P/FCF Ratio0.00
Enterprise Value/Market Cap2.45
Enterprise Value/Revenue3.40
Enterprise Value/Gross Profit5.26
Enterprise Value/Ebitda-8.53
Forecast
1Y Price Target
$4.23Price Target Upside28.57% Upside
Rating ConsensusHold
Number of Analyst Covering5
Revance Therapeutics News
Bulls Say, Bears Say
Bulls Say
Acquisition ProposalTeoxane made a competing bid and offered to purchase Revance for $3.60/share in cash, which represents a 16% premium to Crown's offer.
Financial StabilityTeoxane has substantial cash on hand, is highly profitable, and is in discussions to secure committed financing for the transaction.
Product Line SuccessTeoxane is a 6.2% shareholder of RVNC and is the manufacturer of the RHA filler product line, which represented ~52% of RVNC's total sales.
Bears Say
Capital ConcernsRevance withdrew 2024 product sales guidance of at least $280M following lower-than-expected results.
Financial PerformanceRevance's 3Q results came in far short of expectations with revenues at $59.9M vs consensus at $68.2M.
Merger UncertaintyOngoing discussions with Crown might lead to further delays or modifications to the terms of the merger agreement, creating uncertainty about the deal's completion.
---
Ownership Overview
2.01% Insiders
17.21% Mutual Funds
0.46% Other Institutional Investors
68.42% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RVNC FAQ
What was Revance Therapeutics’s price range in the past 12 months?
Revance Therapeutics lowest stock price was $2.30 and its highest was $7.56 in the past 12 months.
What is Revance Therapeutics’s market cap?
Revance Therapeutics’s market cap is $343.44M.
When is Revance Therapeutics’s upcoming earnings report date?
Revance Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 48 days.
How were Revance Therapeutics’s earnings last quarter?
Revance Therapeutics released its earnings results on Nov 07, 2024. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.269 by -$0.101.
Is Revance Therapeutics overvalued?
According to Wall Street analysts Revance Therapeutics’s price is currently Undervalued.
Does Revance Therapeutics pay dividends?
Revance Therapeutics does not currently pay dividends.
What is Revance Therapeutics’s EPS estimate?
Revance Therapeutics’s EPS estimate is -0.26.
How many shares outstanding does Revance Therapeutics have?
Revance Therapeutics has 104,389,885 shares outstanding.
What happened to Revance Therapeutics’s price movement after its last earnings report?
Revance Therapeutics reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.269. Following the earnings report the stock price went down -35.986%.
Which hedge fund is a major shareholder of Revance Therapeutics?
Among the largest hedge funds holding Revance Therapeutics’s share is Woodline Partners LP. It holds Revance Therapeutics’s shares valued at 4M.
---
Revance Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.23 (28.57% Upside)
$4.23 (28.57% Upside)
Blogger Sentiment
Bullish
RVNC Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 426.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.61%
12-Months-Change
Fundamentals
Return on Equity
111.29%
Trailing 12-Months
Asset Growth
-13.32%
Trailing 12-Months
Company Description
Revance Therapeutics
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Newark, CA.
---
RVNC Earnings Call
Q2 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant growth in DAXXIFY aesthetic sales and a promising start for its therapeutic launch. Financial guidance has improved, and the company remains in a strong financial position. However, the soft filler market and modest initial therapeutic revenues present challenges. Overall, the positive aspects outweigh the negatives, indicating a generally favorable outlook.Read More>---
RVNC Stock 12 Month Forecast
Average Price Target
$4.23
▲(28.57% Upside)
Technical Analysis
Axsome Therapeutics
―
Heron Therapeutics
―
Alkermes
―
Ligand Pharma
―
Marinus
―
RegenXBio
―
Best Analysts Covering RVNC
1 Year
---